Here are five things to know:
1. Hymovis is a next-generation of HA-based intra-articular therapy indicated for the treatment of pain in osteoarthritis of the knee in patients.
2. Scientists from Fidia Farmaceutici and the research group led by Lawrence Bonassar, PhD, professor in the Meinig School of Biomedical Engineering at Cornell University in Ithaca, N.Y., worked together to verify the optimal lubricating characteristics of the HA derivative.
3. Hymovis was bioengineered using a proprietary process that results in a natural hyaluronan similar to the hyaluronan found in the synovial fluid present in human joints.
4. Worldwide, hyaluronic acid-based intra-articular injections are used in the treatment of knee pain due to osteoarthritis of the knee.
5. The FDA gave premarket approval for Hymovis on Aug. 28, 2015, and it will become commercially available in March 2016.
More articles on devices and implants:
Maxx Orthopedics, Invibio develop PEEK-OPTIMA Knee — 5 insights
After strong year-end financials, Wright Medical’s share price spikes 3.8%: 4 points
Anika Therapeutics to enter $25M share repurchase program: 3 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
